WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia: AbbVie Goes On The Offensive With $10.9 Billion Takeover — Warptech Lab News

Storia in 10 fonti

AbbVie Goes On The Offensive With $10.9 Billion Takeover

The deal bolsters AbbVie's immunology and inflammation pipeline, answering a key investor question about what comes after Skyrizi.

Raccontata da

markets.businessinsider.com

valor.globo.com

biopharmadive.com

milanofinanza.it

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

investors.comStai leggendo1 g fa

AbbVie Goes On The Offensive With $10.9 Billion Takeover

The deal bolsters AbbVie's immunology and inflammation pipeline, answering a key investor question about what comes after Skyrizi.

Timeline cronologica

venerdì 19 giugno 2026·markets.businessinsider.com
M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics
Shares in biotechnology company Apogee Therapeutics (APGE) are set to start the new week off in great shape on reports that it could be swallowe...
venerdì 19 giugno 2026·wiwo.de
Pharmaindustrie: AbbVie wohl vor Übernahme von Biotechfirma Apogee Therapeutics
Der Pharmariese aus den USA plant offenbar den Kauf von Apogee Therapeutics. Das Angebot stellt einen deutlichen Aufschlag dar.

1 g fa

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition - AbbVie (NYSE:ABBV), Apogee Ther

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.

Leggi questa versione → originale

biopharmadive.com1 g fa

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster” sales potential.

Leggi questa versione → originale

statnews.com1 g fa

AbbVie to buy Apogee Therapeutics in nearly $11B deal

AbbVie acquires Apogee for $10.9B to add zumilokibart, an immunology drug dosed 2–4 times yearly for inflammatory diseases. The deal signals pharma's trend toward consolidation via focused biotech acquisitions—key signal for partnership and M&A strategy.

Leggi questa versione → originale

endpoints.news1 g fa

AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates

AbbVie strikes a $10.9B deal for Apogee, adding a long-acting IL-13 drug to its Humira-Skyrizi-Rinvoq I&I franchise.

Leggi questa versione → originale

Pharma: AbbVie schluckt Biotechfirma Apogee für 10,9 Milliarden Dollar

AbbVie stärkt mit der Übernahme von Apogee Therapeutics sein Immunologie-Portfolio und setzt auf neue Wachstumstreiber.

Leggi questa versione → originale

venerdì 19 giugno 2026·

expansion.com

AbbVie ultima la compra de la 'biotech' Apogee por 9.500 millones

Seg�n los t�rminos de un potencial acuerdo que est� en fase avanzada y que podr�a anunciarse el lunes, AbbVie pagar� un prima cercana al 60% respecto al cierre en Bolsa de...

sabato 20 giugno 2026·

valor.globo.com

FT: AbbVie está perto de comprar Apogee Therapeutics por US$ 11 bi

Negócio chega em meio a aumento de compras de companhias de biotecnologia e ao interesse das grandes farmacêuticas para reforçar desenvolvimento de remédios

lunedì 22 giugno 2026·

biopharmadive.com

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster”…

lunedì 22 giugno 2026·

endpoints.news

AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates

AbbVie strikes a $10.9B deal for Apogee, adding a long-acting IL-13 drug to its Humira-Skyrizi-Rinvoq I&I franchise.

lunedì 22 giugno 2026·

statnews.com

AbbVie to buy Apogee Therapeutics in nearly $11B deal

AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run of pharma acquisitions.

lunedì 22 giugno 2026·

wiwo.de

Pharma: AbbVie schluckt Biotechfirma Apogee für 10,9 Milliarden Dollar

AbbVie stärkt mit der Übernahme von Apogee Therapeutics sein Immunologie-Portfolio und setzt auf neue Wachstumstreiber.

lunedì 22 giugno 2026·

benzinga.com

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition - AbbVie (NYSE:ABBV), Apogee Ther

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.

lunedì 22 giugno 2026·

investors.com

AbbVie Goes On The Offensive With $10.9 Billion Takeover

The deal bolsters AbbVie's immunology and inflammation pipeline, answering a key investor question about what comes after Skyrizi.

lunedì 22 giugno 2026·

expansion.com

AbbVie compra la 'biotech' Apogee por 10.900 millones de d�lares

Seg�n los t�rminos del acuerdo, AbbVie pagar� un prima cercana al 50% respecto al cierre en Bolsa de Apogee Therapeutics el pasado jueves, ya que el viernes no hubo sesi�n en...

martedì 23 giugno 2026·

milanofinanza.it

AbbVie compra Apogee per 10,9 mld $ | MilanoFinanza News

<p>AbbVie ha raggiunto un accordo per l'acquisizione di Apogee Therapeutics per circa 10,9 miliardi di dollari in contanti, un'operazione che rafforza il portafoglio di farmaci…

martedì 23 giugno 2026·

benzinga.com

AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic

AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term dilution.